Skip to search.

Breaking News Visit Yahoo! News for the latest.

×Close this window

 Dow Up0.34% Nasdaq Up0.16%

Trius Therapeutics, Inc. (TSRX)

-NasdaqGM

7.77 Down 0.11(1.40%) 4:00PM EDT

Add to Portfolio
Income StatementGet Income Statement for:
View: Annual Data | Quarterly DataAll numbers in thousands
Period EndingMar 30, 2013Dec 30, 2012Sep 29, 2012Jun 29, 2012
Total Revenue 1,727   5,156   5,973   6,224  
Cost of Revenue -   -   -   -  
Gross Profit 1,727   5,156   5,973   6,224  
Operating Expenses
Research Development12,545  16,466  19,332  16,379  
Selling General and Administrative4,504  4,653  4,427  3,311  
Non Recurring -   -   -   -  
Others -   -   -   -  
Total Operating Expenses -   -   -   -  
Operating Income or Loss (15,322) (15,963) (17,786) (13,466)
Income from Continuing Operations
Total Other Income/Expenses Net(1,958)1,735  104  (948)
Earnings Before Interest And Taxes(17,280)(14,228)(17,682)(14,414)
Interest Expense -   -   -   -  
Income Before Tax(17,280)(14,228)(17,682)(14,414)
Income Tax Expense -   -   -   -  
Minority Interest -   -   -   -  
Net Income From Continuing Ops(17,280)(14,228)(17,682)(14,414)
Non-recurring Events
Discontinued Operations -   -   -   -  
Extraordinary Items -   -   -   -  
Effect Of Accounting Changes -   -   -   -  
Other Items -   -   -   -  
Net Income (17,280) (14,228) (17,682) (14,414)
Preferred Stock And Other Adjustments -   -   -   -  
Net Income Applicable To Common Shares (17,280) (14,228) (17,682) (14,414)

Sign Up for a Free Trial to EDGAR Online Premium!
Get the critical business and financial information you need for more than 15,000 U.S. public companies.
Sign Up Now - Learn More

Currency in USD.